GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » Beneish M-Score

Essex Bio-Technology (HKSE:01061) Beneish M-Score : -2.32 (As of Dec. 14, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.32 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Essex Bio-Technology's Beneish M-Score or its related term are showing as below:

HKSE:01061' s Beneish M-Score Range Over the Past 10 Years
Min: -3   Med: -2.1   Max: -1.49
Current: -2.32

During the past 13 years, the highest Beneish M-Score of Essex Bio-Technology was -1.49. The lowest was -3.00. And the median was -2.10.


Essex Bio-Technology Beneish M-Score Historical Data

The historical data trend for Essex Bio-Technology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology Beneish M-Score Chart

Essex Bio-Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.05 -2.72 -2.15 -3.00 -2.32

Essex Bio-Technology Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.00 - -2.32 -

Competitive Comparison of Essex Bio-Technology's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Essex Bio-Technology's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Essex Bio-Technology's Beneish M-Score falls into.



Essex Bio-Technology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Essex Bio-Technology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.984+0.528 * 1.0006+0.404 * 1.0263+0.892 * 1.2951+0.115 * 0.7398
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.038+4.679 * -0.022615-0.327 * 0.8821
=-2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was HK$637 Mil.
Revenue was HK$1,707 Mil.
Gross Profit was HK$1,539 Mil.
Total Current Assets was HK$1,245 Mil.
Total Assets was HK$2,828 Mil.
Property, Plant and Equipment(Net PPE) was HK$416 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$60 Mil.
Selling, General, & Admin. Expense(SGA) was HK$1,229 Mil.
Total Current Liabilities was HK$811 Mil.
Long-Term Debt & Capital Lease Obligation was HK$56 Mil.
Net Income was HK$275 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$339 Mil.
Total Receivables was HK$500 Mil.
Revenue was HK$1,318 Mil.
Gross Profit was HK$1,189 Mil.
Total Current Assets was HK$1,214 Mil.
Total Assets was HK$2,712 Mil.
Property, Plant and Equipment(Net PPE) was HK$409 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$42 Mil.
Selling, General, & Admin. Expense(SGA) was HK$914 Mil.
Total Current Liabilities was HK$561 Mil.
Long-Term Debt & Capital Lease Obligation was HK$382 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(637.241 / 1706.556) / (500.057 / 1317.711)
=0.373408 / 0.379489
=0.984

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1189.329 / 1317.711) / (1539.293 / 1706.556)
=0.902572 / 0.901988
=1.0006

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1245.278 + 416.476) / 2827.558) / (1 - (1213.978 + 408.79) / 2712.397)
=0.412301 / 0.401722
=1.0263

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1706.556 / 1317.711
=1.2951

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(41.913 / (41.913 + 408.79)) / (59.876 / (59.876 + 416.476))
=0.092995 / 0.125697
=0.7398

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1228.963 / 1706.556) / (914.189 / 1317.711)
=0.720142 / 0.69377
=1.038

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((56.461 + 810.744) / 2827.558) / ((382.121 + 560.917) / 2712.397)
=0.306698 / 0.347677
=0.8821

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(275.26 - 0 - 339.205) / 2827.558
=-0.022615

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Essex Bio-Technology has a M-score of -2.32 suggests that the company is unlikely to be a manipulator.


Essex Bio-Technology Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Essex Bio-Technology Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Executives
Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin 2101 Beneficial owner

Essex Bio-Technology Headlines

No Headlines